Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.
Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
The Brief Repeatable Battery: psychometrics and normative values with age, education and gender corrections in a Serbian population.
Does interferon Beta-1a impact pure-tone hearing sensitivity among individuals with multiple sclerosis?
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
Food and Drug Administration Approval Letter for Alemtuzumab
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
Ustekinumab.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Modulation of nitric oxide synthase by arginase and methylated arginines during the acute phase of experimental multiple sclerosis.
Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Poor sleep in patients with multiple sclerosis.
Demyelination affects temporal aspects of perception: An optic neuritis study.
The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients.
Remyelination therapy goes to trial for multiple sclerosis

Pages